Suzhou Sirnaomics Biopharmaceuticals Co., Ltd signed share purchase agreement to acquire 4.2% stake in Guangzhou Nanotides Pharmaceuticals Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. for CNY 2.2 million.
January 24, 2021
Share
Suzhou Sirnaomics Biopharmaceuticals Co., Ltd signed share purchase agreement to acquire 4.2% stake in Guangzhou Nanotides Pharmaceuticals Co., Ltd. from Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) for CNY 2.2 million on January 25, 2021. Within 10 working days after the agreement signing date, Suzhou Sirnaomics Biopharmaceuticals Co., Ltd. must make a one-time payment. Within 10 working days from the payment date, the transfer must be completed. After the transfer, Suzhou Sirnaomics Biopharmaceuticals Co., Ltd. will hold 100%. As of December 31, 2020, Guangzhou Nanotides Pharmaceuticals reported total assets of CNY 18.0145 million, net assets of CNY 9.8891 million, revenue of CNY 4.16 million and net profit of CNY 1.6799 million. The transaction does not need the approvals of the Directorate and shareholders of Xiangxue Pharmaceutical.
XIANGXUE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the research, development, production and distribution of traditional Chinese medicines and herbal decoction pieces. The Company's main products include antiviral oral liquids, indigowoad root granules, Exocarpium Citri Reticulatae series Chinese patent drugs and herbal decoction pieces, among others. The Company is also involved in the manufacture and sale of medical devices, health products, soft drinks and biological products. The Company distributes its products in domestic market.
XIANGXUE PHARMACEUTICAL CO.,LTD. 
